These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23181052)

  • 41. Body mass index is inversely correlated with the expanded CAG repeat length in SCA3/MJD patients.
    Saute JA; Silva AC; Souza GN; Russo AD; Donis KC; Vedolin L; Saraiva-Pereira ML; Portela LV; Jardim LB
    Cerebellum; 2012 Sep; 11(3):771-4. PubMed ID: 22090366
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Pipeline to Assess Disease-Associated Haplotypes in Repeat Expansion Disorders: The Example of MJD/SCA3
    Costa IPD; Almeida BC; Sequeiros J; Amorim A; Martins S
    Front Genet; 2019; 10():38. PubMed ID: 30804982
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correlation between CAG repeat length and clinical features in Machado-Joseph disease.
    Maciel P; Gaspar C; DeStefano AL; Silveira I; Coutinho P; Radvany J; Dawson DM; Sudarsky L; Guimarães J; Loureiro JE
    Am J Hum Genet; 1995 Jul; 57(1):54-61. PubMed ID: 7611296
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Analysis of SCA1, DRPLA, MJD, SCA2, and SCA6 CAG repeats in 48 Portuguese ataxia families.
    Silveira I; Coutinho P; Maciel P; Gaspar C; Hayes S; Dias A; Guimarães J; Loureiro L; Sequeiros J; Rouleau GA
    Am J Med Genet; 1998 Mar; 81(2):134-8. PubMed ID: 9613852
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Analysis of CAG trinucleotide expansion associated with Machado-Joseph disease.
    Watanabe M; Abe K; Aoki M; Kameya T; Kaneko J; Shoji M; Ikeda M; Shizuka M; Ikeda Y; Iizuka T; Hirai S; Itoyama Y
    J Neurol Sci; 1996 Mar; 136(1-2):101-7. PubMed ID: 8815156
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of an AAV-Based MicroRNA Gene Therapy to Treat Machado-Joseph Disease.
    Martier R; Sogorb-Gonzalez M; Stricker-Shaver J; Hübener-Schmid J; Keskin S; Klima J; Toonen LJ; Juhas S; Juhasova J; Ellederova Z; Motlik J; Haas E; van Deventer S; Konstantinova P; Nguyen HP; Evers MM
    Mol Ther Methods Clin Dev; 2019 Dec; 15():343-358. PubMed ID: 31828177
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Distribution of the CAG Triplet Repeat in ATXN1, ATXN3, and CACNA1A Loci in Peruvian Population.
    Gonzales-Sáenz C; Cruz-Rodriguez C; Espinoza-Huertas K; Véliz-Otani D; Marca V; Ortega O; Milla-Neyra K; Alvarez-Tejada J; Mazzetti P; Cornejo-Olivas M
    Cerebellum; 2020 Aug; 19(4):527-535. PubMed ID: 32285347
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Somatic mosaicism of the CAG repeat expansion in spinocerebellar ataxia type 3/Machado-Joseph disease.
    Cancel G; Gourfinkel-An I; Stevanin G; Didierjean O; Abbas N; Hirsch E; Agid Y; Brice A
    Hum Mutat; 1998; 11(1):23-7. PubMed ID: 9450899
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Unravelling Endogenous MicroRNA System Dysfunction as a New Pathophysiological Mechanism in Machado-Joseph Disease.
    Carmona V; Cunha-Santos J; Onofre I; Simões AT; Vijayakumar U; Davidson BL; Pereira de Almeida L
    Mol Ther; 2017 Apr; 25(4):1038-1055. PubMed ID: 28236575
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.
    Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M
    Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein.
    Ashraf NS; Sutton JR; Yang Y; Ranxhi B; Libohova K; Shaw ED; Barget AJ; Todi SV; Paulson HL; Costa MDC
    Neurobiol Dis; 2020 Apr; 137():104697. PubMed ID: 31783119
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3.
    Prudencio M; Garcia-Moreno H; Jansen-West KR; Al-Shaikh RH; Gendron TF; Heckman MG; Spiegel MR; Carlomagno Y; Daughrity LM; Song Y; Dunmore JA; Byron N; Oskarsson B; Nicholson KA; Staff NP; Gorcenco S; Puschmann A; Lemos J; Januário C; LeDoux MS; Friedman JH; Polke J; Labrum R; Shakkottai V; McLoughlin HS; Paulson HL; Konno T; Onodera O; Ikeuchi T; Tada M; Kakita A; Fryer JD; Karremo C; Gomes I; Caviness JN; Pittelkow MR; Aasly J; Pfeiffer RF; Veerappan V; Eggenberger ER; Freeman WD; Huang JF; Uitti RJ; Wierenga KJ; Marin Collazo IV; Tipton PW; van Gerpen JA; van Blitterswijk M; Bu G; Wszolek ZK; Giunti P; Petrucelli L
    Sci Transl Med; 2020 Oct; 12(566):. PubMed ID: 33087504
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is the High Frequency of Machado-Joseph Disease in China Due to New Mutational Origins?
    Li T; Martins S; Peng Y; Wang P; Hou X; Chen Z; Wang C; Tang Z; Qiu R; Chen C; Hu Z; Xia K; Tang B; Sequeiros J; Jiang H
    Front Genet; 2018; 9():740. PubMed ID: 30842792
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Age related axonal neuropathy in spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD).
    Klockgether T; Schöls L; Abele M; Bürk K; Topka H; Andres F; Amoiridis G; Lüdtke R; Riess O; Laccone F; Dichgans J
    J Neurol Neurosurg Psychiatry; 1999 Feb; 66(2):222-4. PubMed ID: 10071104
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CRISPR/Cas9 mediated gene correction ameliorates abnormal phenotypes in spinocerebellar ataxia type 3 patient-derived induced pluripotent stem cells.
    He L; Wang S; Peng L; Zhao H; Li S; Han X; Habimana JD; Chen Z; Wang C; Peng Y; Peng H; Xie Y; Lei L; Deng Q; Wan L; Wan N; Yuan H; Gong Y; Zou G; Li Z; Tang B; Jiang H
    Transl Psychiatry; 2021 Sep; 11(1):479. PubMed ID: 34535635
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mutation detection in Machado-Joseph disease using repeat expansion detection.
    Lindblad K; Lunkes A; Maciel P; Stevanin G; Zander C; Klockgether T; Ratzlaff T; Brice A; Rouleau GA; Hudson T; Auburger G; Schalling M
    Mol Med; 1996 Jan; 2(1):77-85. PubMed ID: 8900536
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Spastic paraparesis as the first manifestation of Machado-Joseph disease: A case report and review of the literature.
    Lin HC; Chang YY; Chang KH; Chen YF; Lan MY
    Clin Neurol Neurosurg; 2018 Sep; 172():137-140. PubMed ID: 30007589
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Spinocerebellar ataxia type 1 and Machado-Joseph disease: incidence of CAG expansions among adult-onset ataxia patients from 311 families with dominant, recessive, or sporadic ataxia.
    Ranum LP; Lundgren JK; Schut LJ; Ahrens MJ; Perlman S; Aita J; Bird TD; Gomez C; Orr HT
    Am J Hum Genet; 1995 Sep; 57(3):603-8. PubMed ID: 7668288
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Selection of Reference Genes for Normalization of Gene Expression Data in Blood of Machado-Joseph Disease/Spinocerebellar Ataxia Type 3 (MJD/SCA3) Subjects.
    Ferreira AF; Raposo M; Vasconcelos J; Costa MDC; Lima M
    J Mol Neurosci; 2019 Nov; 69(3):450-455. PubMed ID: 31286408
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improvement in the molecular diagnosis of Machado-Joseph disease.
    Maciel P; Costa MC; Ferro A; Rousseau M; Santos CS; Gaspar C; Barros J; Rouleau GA; Coutinho P; Sequeiros J
    Arch Neurol; 2001 Nov; 58(11):1821-7. PubMed ID: 11708990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.